お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、心血管疾患の遺伝子治療の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別に心血管疾患の遺伝子治療市場を分類しています。
本レポートでは世界の心血管疾患の遺伝子治療市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Renovacor、Gene Biotherapeutics、AskBio、Human Stem Cells Institute、Novartis、Biogen、Gilead Sciences、Sarepta Therapeutics、Alnylam Pharmaceuticals、Amgen、Spark Therapeutics、Akcea Therapeutics、Sunway Biotech、SIBIONO、AnGes、Orchard Therapeutics

レポートは心血管疾患の遺伝子治療の主要生産者を調査し、主要地域や国の消費状況も提供します。心血管疾患の遺伝子治療の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Viral Gene Therapy
    Non-Viral Gene Therapy

用途別の市場セグメント：
    Heart Disease
    Vascular Disease

本レポートの詳細内容
本レポートは、世界の心血管疾患の遺伝子治療市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいて心血管疾患の遺伝子治療市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）の心血管疾患の遺伝子治療生産量、成長率、市場シェアを調査している。

二. 消費面では、心血管疾患の遺伝子治療の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーの心血管疾患の遺伝子治療売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界の心血管疾患の遺伝子治療市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本心血管疾患の遺伝子治療のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：心血管疾患の遺伝子治療のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： 心血管疾患の遺伝子治療の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおける心血管疾患の遺伝子治療の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章心血管疾患の遺伝子治療メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：心血管疾患の遺伝子治療の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：心血管疾患の遺伝子治療の主要メーカーの概要を提供し、製品の説明と仕様、心血管疾患の遺伝子治療の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：心血管疾患の遺伝子治療の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Valued at US$ 586 million in 2024, the global Gene Therapy On Cardiovascular Disease market is forecast to reach US$ 28430 million by 2030, at a CAGR of 91.0% during the forecast period.
Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.
Market Driver: The increasing prevalence of cardiovascular diseases (CVDs) worldwide is a major driver for the gene therapy market in this area. As traditional treatments, such as surgery, medications, and lifestyle changes, sometimes fail to offer long-term solutions, gene therapy presents a promising alternative. By targeting the root causes of CVDs at the genetic level, gene therapy offers the potential for more effective and durable treatments. Advancements in gene editing technologies, such as CRISPR, have further accelerated the development of gene therapies for cardiovascular diseases, allowing for precise modification of genes that regulate heart function, blood vessel health, and inflammation. This technological progress, combined with the growing demand for personalized and innovative treatments, is driving the market forward.Market Challenge: Despite its potential, the gene therapy market for cardiovascular diseases faces several challenges, including high development costs and the complexity of clinical trials. Developing safe and effective gene therapies requires significant investment in research and long-term testing, which can delay the availability of these therapies to patients. Additionally, regulatory approval for gene therapies can be slow and uncertain, creating barriers to rapid commercialization. Moreover, there are concerns regarding the long-term safety and potential unintended genetic consequences of modifying human DNA, which may limit widespread adoption. The complexity of delivering gene therapies to the cardiovascular system, such as targeting specific cells or tissues without causing adverse effects, remains a significant technical challenge.
Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. 
Report Includes
This report presents an overview of global market for Gene Therapy On Cardiovascular Disease market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Gene Therapy On Cardiovascular Disease, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Gene Therapy On Cardiovascular Disease, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Gene Therapy On Cardiovascular Disease revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Gene Therapy On Cardiovascular Disease market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Gene Therapy On Cardiovascular Disease revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Renovacor, Gene Biotherapeutics, AskBio, Human Stem Cells Institute, Novartis, Biogen, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals, Amgen, etc.

Market Segmentation
By Company
    Renovacor
    Gene Biotherapeutics
    AskBio
    Human Stem Cells Institute
    Novartis
    Biogen
    Gilead Sciences
    Sarepta Therapeutics
    Alnylam Pharmaceuticals
    Amgen
    Spark Therapeutics
    Akcea Therapeutics
    Sunway Biotech
    SIBIONO
    AnGes
    Orchard Therapeutics

Segment by Type
    Viral Gene Therapy
    Non-Viral Gene Therapy

Segment by Application
    Heart Disease
    Vascular Disease

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of South America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Gene Therapy On Cardiovascular Disease in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy On Cardiovascular Disease companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy On Cardiovascular Disease revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions

List of Tables
 Table 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Viral Gene Therapy
 Table 3. Key Players of Non-Viral Gene Therapy
 Table 4. Global Gene Therapy On Cardiovascular Disease Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Market Size by Region (2020-2031) & (US$ Million)
 Table 7. Global Gene Therapy On Cardiovascular Disease Market Share by Region (2020-2031)
 Table 8. Market Trends
 Table 9. Market Drivers
 Table 10. Market Challenges
 Table 11. Market Restraints
 Table 12. Global Gene Therapy On Cardiovascular Disease Revenue by Players (2020-2025) & (US$ Million)
 Table 13. Global Gene Therapy On Cardiovascular Disease Market Share by Players (2020-2025)
 Table 14. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
 Table 15. Global Gene Therapy On Cardiovascular Disease Industry Ranking 2023 VS 2024
 Table 16. Global 5 Largest Players Market Share by Gene Therapy On Cardiovascular Disease Revenue (CR5 and HHI) & (2020-2025)
 Table 17. Global Key Players of Gene Therapy On Cardiovascular Disease, Headquarters and Area Served
 Table 18. Global Key Players of Gene Therapy On Cardiovascular Disease, Product and Application
 Table 19. Global Key Players of Gene Therapy On Cardiovascular Disease, Date of Enter into This Industry
 Table 20. Mergers & Acquisitions, Expansion Plans
 Table 21. Global Market Size by Type (2020-2025) & (US$ Million)
 Table 22. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2020-2025)
 Table 23. Global Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 24. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type (2026-2031)
 Table 25. Global Market Size by Application (2020-2025) & (US$ Million)
 Table 26. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2020-2025)
 Table 27. Global Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 28. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2026-2031)
 Table 29. North America Market Size by Type (2020-2031) & (US$ Million)
 Table 30. North America Market Size by Application (2020-2031) & (US$ Million)
 Table 31. North America Gene Therapy On Cardiovascular Disease Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Market Size by Country (2020-2031) & (US$ Million)
 Table 33. Europe Market Size by Type (2020-2031) & (US$ Million)
 Table 34. Europe Market Size by Application (2020-2031) & (US$ Million)
 Table 35. Europe Gene Therapy On Cardiovascular Disease Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 36. Europe Market Size by Country (2020-2025) & (US$ Million)
 Table 37. China Market Size by Type (2020-2031) & (US$ Million)
 Table 38. China Market Size by Application (2020-2031) & (US$ Million)
 Table 39. Asia Market Size by Type (2020-2031) & (US$ Million)
 Table 40. Asia Market Size by Application (2020-2025) & (US$ Million)
 Table 41. Asia Gene Therapy On Cardiovascular Disease Growth Rate (CAGR) by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 42. Asia Market Size by Region (2020-2031) & (US$ Million)
 Table 43. Middle East, Africa, and Latin America Market Size by Type (2020-2031) & (US$ Million)
 Table 44. Middle East, Africa, and Latin America Market Size by Application (2020-2031) & (US$ Million)
 Table 45. Middle East, Africa, and Latin America Gene Therapy On Cardiovascular Disease Growth Rate (CAGR) by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East, Africa, and Latin America Market Size by Country (2020-2031) & (US$ Million)
 Table 47. Renovacor Company Details
 Table 48. Renovacor Business Overview
 Table 49. Renovacor Gene Therapy On Cardiovascular Disease Product
 Table 50. Renovacor Revenue (2020-2025) & (US$ Million)
 Table 51. Renovacor Recent Development
 Table 52. Gene Biotherapeutics Company Details
 Table 53. Gene Biotherapeutics Business Overview
 Table 54. Gene Biotherapeutics Gene Therapy On Cardiovascular Disease Product
 Table 55. Gene Biotherapeutics Revenue (2020-2025) & (US$ Million)
 Table 56. Gene Biotherapeutics Recent Development
 Table 57. AskBio Company Details
 Table 58. AskBio Business Overview
 Table 59. AskBio Gene Therapy On Cardiovascular Disease Product
 Table 60. AskBio Revenue (2020-2025) & (US$ Million)
 Table 61. AskBio Recent Development
 Table 62. Human Stem Cells Institute Company Details
 Table 63. Human Stem Cells Institute Business Overview
 Table 64. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product
 Table 65. Human Stem Cells Institute Revenue (2020-2025) & (US$ Million)
 Table 66. Human Stem Cells Institute Recent Development
 Table 67. Novartis Company Details
 Table 68. Novartis Business Overview
 Table 69. Novartis Gene Therapy On Cardiovascular Disease Product
 Table 70. Novartis Revenue (2020-2025) & (US$ Million)
 Table 71. Novartis Recent Development
 Table 72. Biogen Company Details
 Table 73. Biogen Business Overview
 Table 74. Biogen Gene Therapy On Cardiovascular Disease Product
 Table 75. Biogen Revenue (2020-2025) & (US$ Million)
 Table 76. Biogen Recent Development
 Table 77. Gilead Sciences Company Details
 Table 78. Gilead Sciences Business Overview
 Table 79. Gilead Sciences Gene Therapy On Cardiovascular Disease Product
 Table 80. Gilead Sciences Revenue (2020-2025) & (US$ Million)
 Table 81. Gilead Sciences Recent Development
 Table 82. Sarepta Therapeutics Company Details
 Table 83. Sarepta Therapeutics Business Overview
 Table 84. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product
 Table 85. Sarepta Therapeutics Revenue (2020-2025) & (US$ Million)
 Table 86. Sarepta Therapeutics Recent Development
 Table 87. Alnylam Pharmaceuticals Company Details
 Table 88. Alnylam Pharmaceuticals Business Overview
 Table 89. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product
 Table 90. Alnylam Pharmaceuticals Revenue (2020-2025) & (US$ Million)
 Table 91. Alnylam Pharmaceuticals Recent Development
 Table 92. Amgen Company Details
 Table 93. Amgen Business Overview
 Table 94. Amgen Gene Therapy On Cardiovascular Disease Product
 Table 95. Amgen Revenue (2020-2025) & (US$ Million)
 Table 96. Amgen Recent Development
 Table 97. Spark Therapeutics Company Details
 Table 98. Spark Therapeutics Business Overview
 Table 99. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product
 Table 100. Spark Therapeutics Revenue (2020-2025) & (US$ Million)
 Table 101. Spark Therapeutics Recent Development
 Table 102. Akcea Therapeutics Company Details
 Table 103. Akcea Therapeutics Business Overview
 Table 104. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product
 Table 105. Akcea Therapeutics Revenue (2020-2025) & (US$ Million)
 Table 106. Akcea Therapeutics Recent Development
 Table 107. Sunway Biotech Company Details
 Table 108. Sunway Biotech Business Overview
 Table 109. Sunway Biotech Gene Therapy On Cardiovascular Disease Product
 Table 110. Sunway Biotech Revenue (2020-2025) & (US$ Million)
 Table 111. Sunway Biotech Recent Development
 Table 112. SIBIONO Company Details
 Table 113. SIBIONO Business Overview
 Table 114. SIBIONO Gene Therapy On Cardiovascular Disease Product
 Table 115. SIBIONO Revenue (2020-2025) & (US$ Million)
 Table 116. SIBIONO Recent Development
 Table 117. AnGes Company Details
 Table 118. AnGes Business Overview
 Table 119. AnGes Gene Therapy On Cardiovascular Disease Product
 Table 120. AnGes Revenue (2020-2025) & (US$ Million)
 Table 121. AnGes Recent Development
 Table 122. Orchard Therapeutics Company Details
 Table 123. Orchard Therapeutics Business Overview
 Table 124. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product
 Table 125. Orchard Therapeutics Revenue (2020-2025) & (US$ Million)
 Table 126. Orchard Therapeutics Recent Development
 Table 127. Research Programs/Design for This Report
 Table 128. Key Data Information from Secondary Sources
 Table 129. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 2. Global Gene Therapy On Cardiovascular Disease Market Share by Type: 2024 VS 2031
 Figure 3. Viral Gene Therapy Features
 Figure 4. Non-Viral Gene Therapy Features
 Figure 5. Global Gene Therapy On Cardiovascular Disease Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Global Gene Therapy On Cardiovascular Disease Market Share by Application: 2024 VS 2031
 Figure 7. Heart Disease Case Studies
 Figure 8. Vascular Disease Case Studies
 Figure 9. Gene Therapy On Cardiovascular Disease Report Years Considered
 Figure 10. Global Gene Therapy On Cardiovascular Disease Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 11. Global Gene Therapy On Cardiovascular Disease Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Gene Therapy On Cardiovascular Disease Market Share by Region: 2024 VS 2031
 Figure 13. Global Gene Therapy On Cardiovascular Disease Market Share by Players in 2024
 Figure 14. Global Top Gene Therapy On Cardiovascular Disease Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy On Cardiovascular Disease as of 2024)
 Figure 15. The Top 10 and 5 Players Market Share by Gene Therapy On Cardiovascular Disease Revenue in 2024
 Figure 16. North America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 17. North America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2031)
 Figure 18. North America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2031)
 Figure 19. North America Gene Therapy On Cardiovascular Disease Market Share by Country (2020-2031)
 Figure 20. United States Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Canada Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2031)
 Figure 24. Europe Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2031)
 Figure 25. Europe Gene Therapy On Cardiovascular Disease Market Share by Country (2020-2031)
 Figure 26. Germany Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. France Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. U.K. Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Italy Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Russia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Nordic Countries Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. China Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. China Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2031)
 Figure 34. China Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2031)
 Figure 35. Asia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Asia Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2031)
 Figure 37. Asia Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2031)
 Figure 38. Asia Gene Therapy On Cardiovascular Disease Market Share by Region (2020-2031)
 Figure 39. Japan Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. South Korea Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. China Taiwan Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Southeast Asia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. India Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Australia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. Middle East, Africa, and Latin America Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Middle East, Africa, and Latin America Gene Therapy On Cardiovascular Disease Market Share by Type (2020-2031)
 Figure 47. Middle East, Africa, and Latin America Gene Therapy On Cardiovascular Disease Market Share by Application (2020-2031)
 Figure 48. Middle East, Africa, and Latin America Gene Therapy On Cardiovascular Disease Market Share by Country (2020-2031)
 Figure 49. Brazil Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 50. Mexico Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 51. Turkey Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 53. Israel Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 54. GCC Countries Gene Therapy On Cardiovascular Disease Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 55. Renovacor Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 56. Gene Biotherapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 57. AskBio Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 58. Human Stem Cells Institute Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 59. Novartis Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 60. Biogen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 61. Gilead Sciences Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 62. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 63. Alnylam Pharmaceuticals Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 64. Amgen Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 65. Spark Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 66. Akcea Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 67. Sunway Biotech Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 68. SIBIONO Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 69. AnGes Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 70. Orchard Therapeutics Revenue Growth Rate in Gene Therapy On Cardiovascular Disease Business (2020-2025)
 Figure 71. Bottom-up and Top-down Approaches for This Report
 Figure 72. Data Triangulation
 Figure 73. Key Executives Interviewed